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Objective: To assess whether the difference in risk of
cardiovascular mortality between urban and rural areas of
Serbia could be explained by differences in the use of
cardiovascular medication.
Methods: The Serbian cohorts of the Seven Countries Study,
Velika Krsna (VK), Zrenjanin (ZR) and Belgrade (BG), were
enrolled in 1962-1964 and were followed up for 25 years. The
survivors of these cohorts were re-examined in 1987, 1988
and 1989, respectively. This second examination of elderly
men aged 65 to 84 years included a questionnaire about
current use of cardiovascular medication, risk factors and
diseases and a physical examination. All subjects were followed
until death or the predefined censor date (10 years after
baseline). The Cox proportional hazards model was used to
calculate the risk of cardiovascular mortality in the rural
cohorts compared to the urban cohort and to adjust for
confounding.
Main outcome measure: Cardiovascular death.
Results: A total of 227 men from VK, 184 men from ZR and
287 men from BG were followed for a mean duration of 7.4
years and was complete for all subjects. After exclusion of 13
subjects with missing medication data, the incidences of
cardiovascular mortality in VK, ZR, and BG were 60, 74, and
26 per 1000 person-years, respectively. The prevalence of
cardiovascular medication use was 38% in VK, 52% in ZR, and
59% in BG. The greatest difference in use of specific
medication was observed for betablockers (0% in VK and ZR,
13% in BG). After adjustment for cardiovascular risk factors,
diseases and age, the relative risks (RRs) of cardiovascular
mortality were 2.12 [95% CI: 1.44–3.12], and 2.27 [95% CI:
1.56–3.30] in VK, and ZR compared to BG. Additional
adjustment for the use of cardiovascular medication increased
these RRs to 2.40 [95% CI: 1.61–3.60] and 2.55 [95% CI:
1.72–3.78], respectively.
Conclusion: The variation in cardiovascular medication use
could not explain the excess risk of mortality in the rural
Serbian cohorts compared to urban Belgrade.
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Introduction
Cardiovascular diseases are the major cause of death in
industrialized countries1.
In central Serbia and Vojvodina, a northern province
of Serbia, the contribution of cardiovascular deaths to
deaths from all causes in men is greater than 50%2.
Several cardiovascular drugs have been demonstrated
to be effective in reducing cardiovascular deaths and
morbidity. For instance, the benefits of antihyperten-
sive drug therapy and lipid-lowering drug therapy
have been clearly established in elderly subjects3,4.
However, medical consumption by the elderly seems
to depend on the place of residence. The urban eld-
erly for example, pay more visits to the general practi-
tioner and use more cardiovascular drugs than the ru-
ral elderly5.
A longitudinal study on middle-aged men of the
Serbian cohorts of the Seven Countries Study was ini-
tiated in the period 1962–19642. The cohorts were in-
habitants of the rural village of Velika Krsna, workers in
an agro-industrial cooperative from Zrenjanin, and
university professors from Belgrade. In this study, the
age adjusted 25-year mortality from coronary heart
disease appeared to differ between the cohorts and
was lowest in Belgrade, intermediate in Velika Krsna
and highest in Zrenjanin. Even after adjusting for car-
diovascular risk factors, an unknown but significant
protective factor was identified for the Belgrade co-
hort2. However, this study did not account for the use
of cardiovascular medication. Considering the urban–
rural contrast, patterns of drug use are likely to vary
between the cohorts. This variation of drug consump-
tion may possibly be a cause of the mortality rate dif-
ferences. The present study is a continuation of the 25
years follow-up of the Serbian cohorts. This survey col-
lected both medication data and information on clas-
sical cardiovascular risk factors. The aim of the present
study was to assess whether the difference in risk of
cardiovascular mortality between Belgrade, Zrenjanin,
and Velika Krsna could be explained by differences in
the use of cardiovascular medication.
Method
Setting
The Seven Countries Study is a longitudinal study of
cardiovascular risk factors among 16 cohorts of mid-
dle-aged men, initiated in 19586. The Serbian cohorts
of Velika Krsna, Zrenjanin and Belgrade, were enrolled
in the period 1962–1964 and were followed for 25
years. The survivors of these cohorts were re-examined
in 1987, 1988 and 1989. This examination formed the
baseline of the present study of elderly men aged 65
to 84 years. The study population consisted of 227
men from Velika Krsna, 184 men from Zrenjanin and
287 men from Belgrade. Subjects with missing medi-
cation data (n = 13) were excluded from the analyses.
Velika Krsna is a rural village located about 70 km south
of Belgrade and is inhabited mainly by farmers. The
cohort from Zrenjanin represents the social class of















industrial Combine ‘Servo Mikalj’. Zrenjanin is a town
situated about 70 km north-west of Belgrade in the
province of Vojvodina. The men from Belgrade were
originally working as faculty members of the University
of Belgrade and represent the social class of academ-
ics.
Baseline examinations and data collection
The elderly participants in the Serbian cohorts were
examined at baseline, which took place in the period
1987–1989. The medical examinations were carried
out by trained physicians according to the standard
protocol of the Seven Countries Study6. The examina-
tion included questions about current medication use,
an MRC (Medical Research Council) questionnaire on
cardiovascular and respiratory symptoms, information
on demographic and lifestyle factors and a physical ex-
amination. All men were asked closed-ended ques-
tions about their medication use. At the research cen-
tre subjects were asked to mention all the medication
they used for cardiovascular diseases.
Diagnoses of angina pectoris, myocardial infarction
and claudication were based on a short version of the
MRC questionnaire7,8. Diagnoses from this question-
naire were categorized into present, possible, absent
and unknown. Information on other morbidity was
collected by the Rose questionnaire9, clinical histories
or supplementary questions asked by the examining
physicians. Physician diagnoses were used to assess
stroke, TIA, diabetes, bronchial asthma, emphysema,
chronic bronchitis, malignancy and prostatic diseases.
Smoking habits were examined using a standardized
questionnaire, limited to cigarette smoking6.
Physical examination included measurement of
weight, height, blood pressure, total serum choles-
terol, HDL cholesterol and a resting electrocardio-
gram.
Body weight was measured to the nearest Kilogram
and height to the nearest centimeter. Body mass index
(BMI) was calculated as weight (kg) divided by height
squared (m2). Both diastolic and systolic blood pres-
sure were measured using standard mercury sphyg-
momanometers with the men in supine position. Di-
astolic and systolic blood pressure were reported as
the mean of two consecutive measurements. Total se-
rum and HDL cholesterol (mmol/l) determinations
were carried out in lipid laboratories standardized ac-
cording to the criteria of theWHO Lipid Reference Lab-
oratory10.
Definitions
Medication data were coded according to the ATC sys-
tem11. An additional code was created to define use of
unspecified antihypertensives. Antihypertensive drugs
included low-ceiling diuretics, betablockers, calcium
antagonists, ACE inhibitors, and miscellaneous antihy-
pertensives (centrally acting antiadrenergic agents,
peripherally acting antiadrenergic agents, and other
drugs such as ketanserin). Smoking was defined as cur-
rently smoking more than one cigarette a day. Total
alcohol consumption was calculated as number of
glasses, given the assumption that all alcoholic drinks
(beer, spirits and wine) contain about the same
amount of alcohol. Education was coded as number of
years of education. Cerebrovascular disease (CVA) was
defined as a positive clinical diagnosis of stroke or tran-
sient ischemic attack. Heart disease was defined as a
positive clinical diagnosis of heart failure, myocardial
infarction or angina pectoris. Diabetes represents the
clinically known cases of diabetes. Hypertension was
defined as a diastolic blood pressure > 95 mmHg,
systolic blood pressure > 160 mmHg, or use of antihy-
pertensive medication.
Outcomes
Data on deaths and their causes were obtained
through official death certificates in the population ar-
eas. Death causes were coded by one experienced
physician in a standardized way to ICD-9 categories.
Cardiovascular mortality was defined as death from a
cause belonging to the ICD-9 codes 390–459. A hier-
archical order was used in cases where multiple death
causes were given. The endpoint of the present study
was restricted to the first cause of death only. Consid-
ering the advanced age of the subjects and frequent
uncertainties about etiology of heart disease, there is a
difference in hierarchy between the present coding
and the classical Seven Countries Study (SCS) coding6.
In the present coding, coronary heart disease (ICD-9
codes 410–414) is the only cardiovascular death cause
taking precedence over stroke, whereas in the classical
coding, cardiac dysrhythmias and heart failure (codes
427–428) also take precedence over stroke.
Statistical analyses
All statistical analyses were carried out using the soft-
ware package SPSS version 10.0. Two sample t-tests
were used to compare continuous variables between
cohorts. Chi-square tests were used to analyse cate-
gorical data. A P-value less than 0.05 was considered
statistically significant. The Cox proportional hazards
model12 was used to compare the risk of cardiovascu-
lar death between cohorts and to calculate adjusted
relative risks of cardiovascular death. The Belgrade co-
hort was used as the reference cohort. Subjects with
missing categorical values were kept in analysis by us-
ing an indicator method. For missing continuous data,
the cohort’s mean value was imputed. The Cox model
was used to adjust for age, systolic blood pressure,
present smoking, heart disease, cerebrovascular dis-
ease, diabetes, total and HDL cholesterol and BMI.
Finally, cardiovascular medication variables were in-
cluded to assess their influence on relative risks of car-
diovascular deaths.
A second analysis assessed the risk associated with
specific antihypertensive drugs. This analysis was re-
stricted to hypertensive subjects only in order to re-
duce confounding by indication13. The purpose of this
analysis was to assess whether use of antihypertensive
drugs did reduce the risk of cardiovascular death in this
population.
Results
Great differences in baseline characteristics were ob-
served between the cohorts (Table 1). The men from
Belgrade and Zrenjanin had a higher BMI, higher total
cholesterol levels, more frequently had diabetes, an-
gina pectoris and a history of myocardial infarction,
compared to the men from Velika Krsna. The men
from Velika Krsna and Zrenjanin smoked more often,
had higher blood pressure, and suffered more often
from claudication and heart failure. Educational level
was completely different between the faculty mem- 125
bers from Belgrade and the participants of the rural
cohorts.
Great differences were also observed in cardiovascu-
lar medication use. At baseline, the men from Belgrade
used more cardiovascular medication than the men
from the two other cohorts (Figure 1; P < 0.05). Car-
diovascular medication use was least frequent in the
cohort from the rural village of Velika Krsna. The same
trend was observed for antihypertensive medication.
The use of betablockers was only reported in the base-
line examination of the Belgrade cohort. Relative fre-
quencies of subjects using ACE inhibitors, low ceiling
diuretics and calcium channel blockers were also high-
est for the Belgrade cohort.
Only the group of miscellaneous antihypertensives
appeared to be slightly more common among sub-
jects from Velika Krsna and Zrenjanin, although the dif-
ference was not statistically significant. This group
contained centrally acting antiadrenergic agents, the
combination of rauwolfia alkaloids and diuretics, and
alpha-adrenoceptor antagonists. Vasodilator use was
similar in Belgrade and Zrenjanin but clearly lower in
Velika Krsna. The use of cardiac therapy was highest in
Belgrade, intermediate in Zrenjanin and lowest in Ve-
lika Krsna. In Velika Krsna, 15.3% of the subjects could
not recall the name or type of their anti-hypertensive
medication. In Zrenjanin this occurred in 7.7% of the
subjects whereas in Belgrade this was only 1.4%.
The mean duration of follow-up was 7.4 years and
was complete for all subjects.
The crude incidence rates of cardiovascular death in
Zrenjanin, Velika Krsna and Belgrade were 74.5, 60.4
and 25.5 per 1000 person-years, respectively.
The subjects from Velika Krsna had a two-fold higher
risk of cardiovascular death (RR, 2.32: 95%CI = 1.68–
3.21) compared to the subjects from the reference co-
hort Belgrade (Table 2). The relative risk of cardiovas-
cular death was highest in the Zrenjanin cohort (RR,
2.91: 95% CI = 2.09–4.04). After adjusting for tradi-
tional cardiovascular risk factors, the relative risks of
cardiovascular death in Velika Krsna and Zrenjanin
compared to Belgrade dropped to 2.12 and 2.27, re-
spectively.
Finally, the use of antihypertensives and cardiac
therapy were included in the model. The use of beta-
blockers, ACE inhibitors, and unknown anti-hyperten-
sives could not be included as separate variables in the
model, because these drugs were not used in all co-
horts. Therefore, we had to create one comprehensive
variable that indicated whether subjects used antihy-
Table 1 Characteristics of the 3 Serbian cohorts of men aged 65 to 84 at baseline
Belgrade Velika Krsna Zrenjanin
Na Na Na
Number 282 222 181

















Mycardial infarction, % 281 8.2 186 1.6# 176 6.8
Angina pectoris, % 281 10.3 187 3.7# 176 11.9
Claudication, % 279 5.0# 187 16.0# 178 30.3
Heart failure, % 280 2.5 222 6.3 177 5.6
Diabetes, % 279 11.1 222 0.9# 176 8.5
Currently smoking, % 278 11.9# 194 33.0 175 25.1
Never smoking, % 278 53.2# 194 35.6 175 36.6










BMI, kg/m2 259 26.1 196 23.3# 155 26.6
Total serum cholesterol, mmol/l 194 6.34 163 5.41# 147 6.29
HDL, mmol/l 193 1.26# 144 1.31 145 1.37
Data are given as means unless otherwise indicated.
a Number of subjects with measurements.
 P < 0.05 versus Velika Krsna; # P < 0.05 versus Zrenjanin.
Figure 1 Cardiovascular medication use at baseline
(1987–1989) in Serbian men aged 65 to 84 years. Car-
diovascular drugs includes all cardiovascular drugs. Anti-
hypertensive drugs includes betablockers, low ceiling diu-
retics, calcium channel blockers, ACE inhibtors, vasodila-
tors, miscellaneous anti-hypertensives, and unknown
anti-hypertensives.
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pertensive drugs or not. The use of vasoprotectives,
serum lipid lowering agents, high ceiling diuretics and
potassium sparing agents was too infrequent to be in-
cluded the model. The inclusion of the cardiovascular
medication variables resulted in increased adjusted rel-
ative risks of cardiovascular death in Velika Krsna (RR:
2.33, 95% CI: 1.57–3.45) and Zrenjanin (RR: 2.46,
95% CI: 1.68–3.60) compared to Belgrade (Table 3).
In a second analysis we compared users of specific
antihypertensive drugs with untreated hypertensive
subjects. The adjusted relative risks of cardiovascular
death were 0.97 (95% CI: 0.53–1.77) for calcium
channel blockers, 1.26 (95%CI: 0.71–2.22) for vasodi-
lators, 0.71 (95% CI: 0.42–1.20) for miscellaneous an-
tihypertensives, 1.81 (95% CI: 0.84–3.94) for low ceil-
ing diuretics and 1.43 (95% CI: 0.81–2.51) for combi-
nations of anti-hypertensives. The use of ACE inhibitors
was too infrequent, whereas the risk associated with
the use of betablockers could only be assessed in Bel-
grade. The relative risk of cardiovascular death associ-
ated with the use of betablockers was 0.53 (95% CI:
0.21–1.36) in Belgrade.
The adjusted relative risk of cardiovascular death
among antihypertensive users (n = 284) was 0.91
(95% CI: 0.64–1.30) compared with the untreated hy-
pertensives (n = 125).
Discussion
Cardiovascular mortality rates were substantially dif-
ferent between the cohorts. Highest death rates were
observed in Zrenjanin (74.5/1000 person-years), inter-
mediate death rates in Velika Krsna (60.4/1000 per-
son-years), and lowest death rates in Belgrade (25.5/
1000 person-years). The great differences in cardiovas-
cular drug use between the cohorts did not explain the
observed differences in cardiovascular mortality.
Several studies have examined patterns of medica-
tion14–16 or cardiovascular mortality differences17,18
among the elderly, but few studies have assessed asso-
ciations between drug use patterns and cardiovascular
mortality.
A possible causal factor for the observed differences
in cardiovascular survival between the cohorts may be
the great differences in socioeconomic status. Socio-
economic status was found to be a strong and consist-
ent predictor of cardiovascular mortality in a large
number of studies19–22, and this effect seems to per-
sist after retirement23.
There is substantial evidence that socioeconomic
status is inversely associated with cardiovascular risk
factors, particularly hypertension24. This is in agree-
ment with the present study as the average blood
pressure values were higher in the cohorts of Velika
Krsna and Zrenjanin than in the cohort of Belgrade.
However, cardiovascular risk factors could only explain
a small part of the difference in risk of cardiovascular
death between the Serbian cohorts. In other studies,
confounding by risk factors only partly explained the
association between socioeconomic status and cardio-
vascular mortality23,24. Therefore, socio-economic sta-
tus is likely to have an independent, additional effect
on cardiovascular mortality.
The mechanism through which socioeconomic sta-
tus affects cardiovascular mortality is not certain, but
psychosocial factors and economic factors as well as an
influence on lifestyle factors, problem-solving abilities
and values may play an important role23,24. In this
study, lifestyle factors were partly considered by in-
cluding smoking and cholesterol variables. However,
these variables only explained a small part of the mor-
tality differences between Belgrade and the two other
cohorts.
Another factor that may have caused mortality rate
differences is access to medical services. It has been
shown that the urban elderly make more use of local
health services than the rural elderly25,26. In addition,
quality of care may have been better in the Belgrade
cohort and this may have been a cause of the lower
mortality rate in this cohort.
The main strength of the study is the standardized
mode of data collection and the prospective design.
Due to the extensive monitoring system, no subjects
were lost to follow up. Several limitations of this study
have to be considered. As the cohorts represented
three different social classes, no adjustment could be
made for this potential predictor of cardiovascular
death. Data on alcohol use was not collected in Velika
Krsna and therefore could not be included in the mod-
els. Medication variables that could not be included in
the model were vasoprotectives, serum lipid lowering
agents, high ceiling diuretics and potassium sparing
diuretics. However, because of the low prevalence of
these medications, their influence is negligible. Medi-
cation use was based on self-reports and physician or
pharmacy data were not available. It might be possi-
ble that underreporting of medication occurred in the
rural and instrial cohorts compared to the academic
cohort. However, this would have resulted in an un-
derestimation of the effect of differences in medication
use on cardiovascular mortality between the cohorts.
Another factor which was not considered in the
analysis was adherence to drug instructions. Most
studies, however, do not find a clear relationship link-
ing socioeconomic status measurements to poor ad-
herence in hypertensive patients27. Therefore, we












Belgrade 282 61 2389.8 1.00 1.00 1.00
Velika Krsna 222 95 1572.2 2.32 1.68–3.21 2.12 1.44–3.12 2.40 1.61–3.60
Zrenjanin 181 85 1140.9 2.91 2.09–4.04 2.27 1.56–3.30 2.55 1.72–3.78
a Adjusted for age, systolic blood pressure, present smoking, heart disease, cerebrovascular disease, diabetes, total serum cholesterol,
HDL cholesterol and body mass index.
b Adjusted for risk factors and medication variables (anti-hypertensives and cardiac therapy).
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have no indications that adherence was substantially
different between the cohorts. However, poor compli-
ance could diminish the impact of differences in medi-
cation use between the cohorts. Another limitation is
that all analyses were based on single point measure-
ments (medication use, blood pressure, etc.) and
changes over time were not considered.
An important message for health care professionals
may be that our findings suggest that the impact of
cardiovascular drug therapy on cardiovascular mortal-
ity in the population at large may be less important
than life style, which is strongly associated with socio-
economic class. Therefore, efforts to improve cardio-
vascular risk in the population should not only focus on
drug therapy, but should also include the promotion
of life style modifications.
Conclusion
In conclusion, the variation in cardiovascular medica-
tion use could not explain the greater risk of cardiovas-
cular mortality in the rural Serbian areas compared to
the urban Belgrade area. Other factors such as socio-
economic class are more important in risk of CVDmor-
tality.
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